PP
BBIO icon

PDT Partners’s BridgeBio Pharma BBIO Stock Holding History

PDT Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-117,292
Closed -$894K – 578
2022
Q4 		$894K Sell
117,292
-9,001
-7% -$86.2K 0.14% 255
2022
Q3 		$1.25M Buy
+126,293
New +$1.31M 0.19% 159
2022
Q2 		– Sell
-55,433
Closed -$563K – 959
2022
Q1 		$563K Buy
+55,433
New +$569K 0.05% 546

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

PDT Partners's BBIO Position: Q1 2023 in Review

PDT Partners sold out of BridgeBio Pharma (BBIO) in Q1 2023, closing a stake of 117,292 shares — an estimated $894K sold.

PDT Partners first reported a position in BBIO in Q1 2022 and held it in 3 quarters. The position peaked at $1.25M in Q3 2022. 213 funds tracked by Wall St. Rank hold BBIO as of Q1 2023.

  • PDT Partners reported no remaining BridgeBio Pharma position as of Q1 2023 after selling out during the quarter.
  • PDT Partners sold 117,292 BridgeBio Pharma shares in Q1 2023, an estimated $894K.
  • PDT Partners first reported a position in BridgeBio Pharma in Q1 2022 and held it in 3 quarters.
  • PDT Partners's BridgeBio Pharma position peaked at $1.25M in Q3 2022.
  • 213 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2023.

Based on PDT Partners's 13F filing for Q1 2023, filed 15 May 2023.